肝优先基础胰岛素聚乙二醇化赖脯胰岛素对糖尿病患者核磁共振生物标志物脂蛋白胰岛素抵抗指数和糖化白蛋白的影响。
Effects of hepato-preferential basal insulin peglispro on nuclear magnetic resonance biomarkers lipoprotein insulin resistance index and GlycA in patients with diabetes.
作者信息
Connelly Margery A, Otvos James D, Zhang Qianyi, Zhang Shuyu, Antalis Caryl J, Chang Annette M, Hoogwerf Byron J
机构信息
Laboratory Corporation of America Holdings, Morrisville, NC 27560, USA.
Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
出版信息
Biomark Med. 2017 Nov;11(11):991-1001. doi: 10.2217/bmm-2017-0112.
AIM
To characterize the effects of hepato-preferential basal insulin peglispro (BIL) and insulin glargine on insulin resistance (lipoprotein insulin resistance index [LP-IR]) and inflammation (GlycA), and to explore the biological implications.
METHODS
This substudy included 847 patients with Type 1 diabetes (T1D) or Type 2 diabetes (T2D) in four cohorts of the BIL development program. LP-IR and GlycA were measured before and after insulin treatment. Correlations between LP-IR, GlycA, clinical parameters and liver biomarkers were assessed.
RESULTS
LP-IR and GlycA were higher in T2D than T1D. LP-IR increased in patients switched from basal insulins to BIL but not in insulin-naive patients. GlycA decreased in T2D patients treated with BIL and T1D patients treated with glargine.
CONCLUSION
These exploratory analyses help to characterize differences in biological effects between BIL and glargine treatment.
目的
表征肝优先基础胰岛素聚乙二醇化赖脯胰岛素（BIL）和甘精胰岛素对胰岛素抵抗（脂蛋白胰岛素抵抗指数[LP-IR]）和炎症（糖化白蛋白[GlycA]）的影响，并探讨其生物学意义。
方法
该亚研究纳入了BIL研发项目四个队列中的847例1型糖尿病（T1D）或2型糖尿病（T2D）患者。在胰岛素治疗前后测量LP-IR和GlycA。评估LP-IR、GlycA、临床参数和肝脏生物标志物之间的相关性。
结果
T2D患者的LP-IR和GlycA高于T1D患者。从基础胰岛素转换为BIL的患者LP-IR升高，但初治患者未升高。接受BIL治疗的T2D患者和接受甘精胰岛素治疗的T1D患者GlycA降低。
结论
这些探索性分析有助于表征BIL和甘精胰岛素治疗在生物学效应上的差异。
Zotero 插件